文献速递脑血管病

AX-024抑制抗原特异性T细胞反应并改善小鼠脑出血结局

AX-024 Inhibits Antigen-Specific T-Cell Response and Improves Intracerebral Hemorrhage Outcomes in Mice.
PubMed 文献 · Stroke · 2025-03-27

研究在胶原酶诱导的小鼠脑出血模型中腹腔注射TCR信号小分子抑制剂AX-024,发现其可在脑出血后36小时和3天抑制脑内非特异性及抗原特异性CD3+CD4+和CD3+CD8+细胞活化,并减轻早期神经炎症、改善结局且不增加肺部细菌载量。

要点

  • AX-024在脑出血后48小时内给药,可抑制脑内CD3+CD4+和CD3+CD8+细胞活化。
  • AX-024在脑出血后36小时和3天抑制外周抗原特异性T细胞活化,7天时无此作用。
  • AX-024改善幼年雄性小鼠脑出血结局且不增加肺部细菌载量。

核心结论

  • AX-024可能是有前景的选择,可减轻T细胞进入受损脑组织的有害效应而不增加肺部细菌载量。
  • AX-024作为脑出血强效免疫抑制治疗的潜力是令人兴奋的前景,需进一步研究。

研究设计与样本

  • 研究将胶原酶VII-S注射至年轻成年(10-12周)雄性和雌性及老龄(18-20个月)雄性C57BL/6小鼠左侧纹状体建立脑出血模型。
  • 研究腹腔注射TCR信号小分子抑制剂AX-024,并用流式细胞术、蛋白质印迹、免疫荧光染色、组织学染色、细菌培养和行为学测试评估结果。

主要发现

  • 在年轻成年雄性小鼠中,脑出血后48小时内给予AX-024抑制了脑出血后36小时和3天脑内非特异性及抗原特异性CD3+CD4+和CD3+CD8+细胞的活化,但7天时无此作用。
  • AX-024在上述2个时间点暂时抑制外周抗原特异性T细胞活化。
  • AX-024在脑出血早期减轻出血脑内的分子和细胞神经炎症。
  • 在年轻成年雄性小鼠中,AX-024对脑和 periphery 的这些效应最终改善了脑出血结局,同时对肺部细菌载量无影响。
  • 年轻成年雌性和老龄雄性小鼠脑出血中的类似发现进一步支持上述结果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出AX-024作为脑出血强效免疫抑制治疗的潜力是令人兴奋的前景,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stroke-induced opposite T-cell responses in the peri-lesion area and periphery worsen stroke outcomes by aggravating brain injury or increasing infectious complications, respectively. Despite their well-known role in T lymphocyte activation, the impact of TCRs (T-cell receptors) on stroke remains poorly understood. In this study, we investigated the causal link between TCRs and the opposite T-cell responses observed in intracerebral hemorrhage (ICH). METHODS: We established the ICH model by injecting the collagenase VII-S into the left striatum of young adult (10-12 weeks) male and female and aged (18-20 months) male C57BL/6 mice. We intraperitoneally administered AX-024, a small molecule inhibitor of TCR signaling, and evaluated the results using flow cytometry, Western blotting, immunofluorescence staining, histological staining, bacterial culture, and behavioral tests. RESULTS: Our findings in young adult male mice indicate that administering AX-024 within 48 hours suppressed the activation of nonspecific and antigen-specific CD3 (cluster of differentiation 3)+CD4+ and CD3+CD8+ cells in the brain 36 hours and 3 days after ICH but not 7 days after. Additionally, it temporarily inhibited antigen-specific T-cell activation in the periphery at the above 2 time points. It also reduced molecular and cellular neuroinflammation in the hemorrhagic brain early after ICH. These effects in the brain and periphery of young adult male mice ultimately improved ICH outcomes while having no impact on lung bacterial loads. This can be further supported by similar findings in young adult female and aged male mice with ICH. CONCLUSIONS: AX-024 may represent a promising option for mitigating the detrimental effects of T cells entering the damaged brain without increasing bacterial loads in the lung in ICH. The potential of AX-024 as a potent immunosuppressive treatment for ICH is an exciting prospect that warrants further investigation.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Chen S, Fu P, Rastegar-Kashkooli Y, et al. AX-024 Inhibits Antigen-Specific T-Cell Response and Improves Intracerebral Hemorrhage Outcomes in Mice. Stroke. 2025. PMID: 40143825. doi:10.1161/STROKEAHA.124.048507

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。